COMPANY
Rerx Therapeutics, Inc.
Funding and NIH signals
- NIH award NIH awarded $1.31M (SBIR Phase II 5R44DK142483-02, continuation, notice Jul 6, 2026). NIH RePORTER 5R44DK142483-02 (Jul 6, 2026)
Evidence (1 event)
- Jul 6, 2026 · NIH RePORTER 5R44DK142483-02
Organization: RERX THERAPEUTICS, INC; City/State: BERKELEY, CA; Project number: 5R44DK142483-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-06; FY total cost (award amount): 1307195; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Evaluation of novel small molecule targeting lipid and energy homeostasis for treating obesity; Organization type: Domestic For-Profits
- Jul 6, 2026 · NIH RePORTER 5R44DK142483-02